25国甲状腺癌组织学亚型发病率趋势:基于人群研究
该研究基于国际癌症研究机构(IARC)1998-2012年数据,分析25国20-84岁人群甲状腺癌发病率趋势。滤泡状和髓样癌趋势不一致,未分化癌在21/25国略有下降。
要点
- 乳头状癌是唯一在所有研究国家均系统性增加的亚型,国家间差异大。
- 未分化癌在21/25国1998-2002至2008-12年间略有下降。
核心结论
- 1998-2012年间甲状腺癌发病率的快速增加仅见于乳头状癌,该亚型更可能以亚临床形式存在并被甲状腺的仔细检查所发现。
研究设计与样本
- 基于人群研究,数据来自IARC的《五大洲癌症发病率》汇编,覆盖25国87个登记处,纳入20-84岁人群,要求未指明甲状腺癌比例低于10%。
- 计算年龄别和年龄标化发病率(每10万人年),基于1998-2002与2008-12年间年龄标化发病率的绝对变化评估趋势。
主要发现
- 乳头状癌是所有研究国家甲状腺癌的主要贡献者,且是唯一在所有国家均系统性增加的亚型,但国家间变异大。
- 许多亚洲国家女性乳头状癌发病率在2000年后增加尤为明显;美国、奥地利、克罗地亚、德国、斯洛文尼亚、西班牙、立陶宛和保加利亚的发病率自2009年左右趋于稳定。
- 滤泡状和髓样癌的时间趋势在国家间无一致模式;未分化癌在21/25国1998-2002至2008-12年间略有下降。
关键数值与推荐
- 2008-12年髓样癌年龄标化发病率在女性和男性中均始终低于1例/10万人。
临床怎么用
- 内分泌科医生应了解乳头状癌发病率的上升趋势及国家间巨大差异,警惕过度诊断可能。
- 对于滤泡状、髓样癌和未分化癌,发病率趋势相对稳定或下降,临床关注点应侧重于乳头状癌的合理管理。
局限性
- 研究仅纳入25个具备高质量癌症登记数据的国家,结果外推需谨慎。
- 分析限于20-84岁人群,未涵盖其他年龄组。
- 未指明甲状腺癌比例低于10%的登记处被排除,可能影响代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of thyroid cancer has increased in different populations worldwide in the past 30 years. We present here an overview of international trends of thyroid cancer incidence by major histological subtypes. METHODS: We did a population-based study with data for thyroid cancer incidence collected by the International Agency for Research on Cancer (IARC) for the period 1998-2012. Data were extracted from the Cancer Incidence in Five Continents plus compendium. We selected data for 25 countries that had a population of more than 2 million individuals covered by cancer registration (87 registries in total). Further criteria were that the selected registration areas had to have a proportion of unspecified thyroid cancer of less than 10% and analyses were restricted to individuals aged 20-84 years. We calculated age-specific incidence rates and age-standardised rates per 100 000 person-years for individuals aged 20 to 84 years, and assessed trends by country, sex, and major histological subtype (papillary, follicular, medullary, or anaplastic) based on absolute changes in age-standardised incidence rates between 1998-2002 and 2008-12. FINDINGS: Papillary thyroid cancer was the main contributor to overall thyroid cancer in all the studied countries, and was the only histological subtype that increased systematically in all countries, although with large variability between countries. In women, the age-standardised incidence rate of papillary thyroid cancer during 2008-12 ranged from 4·3-5·3 cases per 100 000 person-years in the Netherlands, the UK, and Denmark, to 143·3 cases per 100 000 women in South Korea. For men during the same period, the age-standardised incidence rates of papillary thyroid cancer per 100 000 person-years ranged from 1·2 cases per 100 000 in Thailand to 30·7 cases per 100 000 in South Korea. In many countries in Asia, the increase in papillary thyroid cancer rates in women was particularly pronounced after the year 2000; rates stabilised since around 2009 in the USA, Austria, Croatia, Germany, Slovenia, Spain, Lithuania, and Bulgaria. Temporal trends for follicular and medullary thyroid cancer did not show consistent patterns across countries, but slight decreases were seen for anaplastic thyroid cancer in 21 of 25 countries between 1998-2002, and 2008-12. In 2008-12, age-standardised rates for the follicular subtype ranged between 0·5 and 2·5 cases per 100 000 women (and between 0·3 and 1·5 per 100 000 men), while those for the medullary subtype were always less than 1 case per 100 000 women or men, and for anaplastic thyroid cancer less than 0·2 cases per 100 000 women or men. INTERPRETATION: In the period from 1998 to 2012, the rapid increases in thyroid cancer incidence were observed only for papillary thyroid cancer, the subtype more likely to be found in a subclinical form and therefore detected by intense scrutiny of the thyroid gland. FUNDING: French Institut National du Cancer, Italian Association for Cancer Research, Italian Ministry of Health.
引用
- Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021. PMID: 33662333. doi:10.1016/S2213-8587(21)00027-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。